A
Agilent Technologies Inc
A · Healthcare Technology
Company brief
A
AHealthcare Technology$38.2B

Agilent Technologies Inc

Global leader in analytical instruments, software, services, and consumables for laboratories across life sciences, diagnostics, and applied chemical markets

Moat score
9.2/100
13F status
Tracking pending
Main Metrics

Beginner valuation check

Price
$113
Next earnings
Data pending

Data pending from FMP or Finnhub.

1Y Performance
-0.6%

Negative price performance shows recent market sentiment, not a full investment thesis.

Forward P/E
18.3x

Forward P/E around 18.3x means investors pay about $18.3 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.

P/E
24.5x

A P/E around 24.5x means investors pay about $24.5 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.

EPS
$4.53
Market Cap
$31.6B
Forward P/E is the cleanest beginner valuation anchor here; compare it with growth and recent performance.

Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.

Scenario Framework

Bull / Neutral / Bear

Neutral Case

Agilent keeps converting its installed base into steady laboratory workflow value while investors focus on how the current forward multiple compares with growth.

Watch signal

Forward P/E around 18.3x remains reasonable versus growth.

What you own

Agilent Technologies Inc is exposure to healthcare technology operating model with high switching costs and 108% net revenue retention.

Base thesis

Mission-critical instruments with 15-20 year lifecycles create sticky recurring service revenue

Main risk

The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.

How to inspect it

Pro access unlocks the workflow simulator for this company brief.

Simulator coverage pending

This ticker has a company brief, but richer workflow modules have not been built yet.

Investor Snapshot
9.2Moat Score
Net Revenue Retention108%
Retention RiskLow
AI Disruption RiskLow
Switching CostsHigh
13F Ownership
Tracking pending

No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.

Investment Thesis
  • Mission-critical instruments with 15-20 year lifecycles create sticky recurring service revenue
  • Proprietary consumables (columns, reagents) generate 40%+ gross margins with automatic reordering
  • Validated analytical methods require months/years to transfer to competitor platforms
  • Regulatory compliance (FDA, EPA) creates switching friction - customers avoid revalidation costs
  • Deep scientific expertise and Ph.D. field support impossible for new entrants to replicate
  • AI enhances rather than replaces - improves method optimization and data analysis workflows